SEC Company Response from Korro Bio, Inc. (KRRO) (CIK 0001703647) (KRRO) — Sep 30, 2019
Korro Bio, Inc. (KRRO) (CIK 0001703647)
Date: Sept. 30, 2019 · CIK: 0001703647 · Accession: 0001193125-19-258819
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233652
Letter
Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Attention: Donald Field Re: Frequency Therapeutics, Inc. Registration Statement on Form S-1 Filed September 6, 2019 Registration No. 333-233652
Dear Mr. Field:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on October 2, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Frequency Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Frequency Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 30, 2019 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Donald Field Re: Frequency Therapeutics, Inc. Registration Statement on Form S-1 Filed September 6, 2019 Registration No. 333-233652 Dear Mr. Field: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on October 2, 2019, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Frequency Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Nathan Ajiashvili of Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Jennifer Yoon at (617) 880-4540, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Frequency Therapeutics, Inc. By: /s/ David L. Lucchino David L. Lucchino President and Chief Executive Officer cc: Nathan Ajiashvili, Esq. Jennifer A. Yoon, Esq.